Surrozen, Inc./DE Logo

Surrozen, Inc./DE

Develops regenerative antibodies modulating the Wnt pathway to repair tissues and restore organs.

SRZN | US

Overview

Corporate Details

ISIN(s):
KYG2445M1033 (+2 more)
LEI:
Country:
United States of America
Address:
171 OYSTER POINT BLVD, 94080 SOUTH SAN FRANCISCO
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Surrozen, Inc. is a clinical-stage biotechnology company that discovers and develops drug candidates to repair tissues and restore organs damaged by serious diseases. The company is pioneering a new class of targeted regenerative antibodies designed to selectively modulate the Wnt pathway, a key biological mechanism for the body's natural repair and self-renewal processes. Surrozen's platform develops tissue-specific antibodies with a current focus on therapeutic areas such as ophthalmology. The company's mission is to unlock the body's regenerative power to transform the treatment of a broad range of injuries and diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Surrozen, Inc./DE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Surrozen, Inc./DE

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Surrozen, Inc./DE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

PRAP Japan,Inc. Logo
A PR & communications firm building brand reputation for corporate clients in diverse industries.
Japan
2449
Predictive Oncology Inc. Logo
AI platform uses a vast tumor biobank to predict drug response and accelerate oncology discovery.
United States of America
POAI
Prime Medicine, Inc. Logo
Developing 'search and replace' gene editing therapies to treat genetic disorders.
United States of America
PRME
ProPhase Labs, Inc. Logo
Genomics, diagnostics, contract manufacturing, and OTC health & wellness solutions provider.
United States of America
PRPH
PROTHENA CORP PUBLIC LTD CO Logo
Advancing antibody-based therapies for neurodegenerative and rare amyloid diseases.
United States of America
PRTA
Psomagen, Inc. Logo
A CRO providing multiomics services & data analysis for academic, biotech, and pharma researchers.
United States of America
950200
Public Policy Holding Company, Inc. Logo
Advisory group providing public policy, government relations, and strategic communications services.
United States of America
PPHC.L
Purple Biotech Ltd. Logo
Developing cancer therapies to overcome tumor immune evasion and drug resistance.
Israel
PPBT
Qualigen Therapeutics, Inc. Logo
A clinical-stage company developing innovative treatments for rare cancers in adults and children.
United States of America
QLGN
QUIA PHARMA AB Logo
Develops biobetters by enhancing approved drugs with a patented drug delivery platform.
Sweden
QUIA

Talk to a Data Expert

Have a question? We'll get back to you promptly.